Managing Stress Amid a Pandemic
A lymphoma diagnosis can be challenging to cope with at any time, but the current…
Lymphoma News
Ask the Doctor: How can biomarker testing help DLBCL patients?
The emergence of biomarking testing has provided new insights into the molecular and genetic underpinnings…
Ask the Doctor: What do lymphoma patients need to know about the COVID-19 vaccines?
On December 11 and 18, 2020 the U.S. Food and Drug Administration (FDA) issued two…
Ask the Doctor: Are there clinical trials showing that CAR-T is an effective treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?
In May 2020, lymphoma-expert, Raghuveer Ranganthan, MD (Univerity of Southern California) hosted the Lymphoma Research…
Ask the Doctor: How can patients access innovative drug treatments when insurance won’t cover the cost?
During the Lymphoma Research Foundation’s Denver Ask the Doctor About Lymphoma Program, lymphoma-expert and program…
Trading Places: A Father and Daughter’s Journey with Lymphoma
A father and daughter’s story as both lymphoma survivors and each other’s caregivers, and their mission to empower themselves through education and connect with others at Lymphoma Research Foundation (LRF)’s North American Educational Forum on Lymphoma.
Buildings and Landmarks Join LRF to Light Red and Raise Awareness for Blood Cancer Awareness Month
The tenth anniversary of the Lymphoma Research Foundation’s Blood Cancer Awareness Month initiative expected to reach millions.
Patient Perspectives: Using Consistent Terminology for Biomarker and Germline Genetic Testing
A multi-stakeholder working group recommends consistent biomarker, genetic and genomic testing terminology for patient education and clinical care.
U.S. Food and Drug Administration Approves Tafasitamab-cxix (MONJUVI) for Diffuse Large B-cell Lymphoma (DLBCL)
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved…
U.S. Food and Drug Administration Approves First CAR T Cell Therapy for Mantle Cell Lymphoma: Brexucabtagene Autoleucel (TECARTUS)
Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.
Stay informed with news, alerts and other resources.
